Last reviewed · How we verify
NCT06111833
Optimized Diagnosis and Precision Medicine of MODY
trial in Maturity-Onset Diabetes of the Young (MODY) in 1,500 participants. Currently enrolling.
21 April 2028
Quick facts
| Lead sponsor | Taichung Veterans General Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 22 May 2023 |
| Primary completion | 21 April 2028 |
| Estimated completion | 21 May 2028 |
| Sites | 1 location across Taiwan |
Conditions studied
- Maturity-Onset Diabetes of the Young (MODY) — all drugs for Maturity-Onset Diabetes of the Young (MODY) →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Diabetes Complications — all drugs for Diabetes Complications →
Sponsor
Taichung Veterans General Hospital
Who can join
18 and older, any sex, with Maturity-Onset Diabetes of the Young (MODY) or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observation is to establish a complete registry for the clinical manifestations, environment, genetic, and other related gene variation information of young-onset diabetic patients. Moreover, according to the physiological and pathological mechanisms of different genes, the impact on the clinical characteristics of diabetes, the therapeutic response to drugs, and the impact on complications will be analyzed. The main questions are: 1. The distribution of different types of MODY 2. The phenotypes and clinical characteristics of different types of MODY 3. Response to antidiabetic drugs among different types of MODY Once the participant is enrolled, their questionnaire information (including disease course and development, health history, family history, drug history, etc.), medication, outpatient/inpatient medical history, etc. will be collected and logged in. Blood and urine samples will also be collected for biochemical tests genetic testing, etc. At the same time, the investigators will conduct a continuous follow-up on a regular basis (3 months, 6 months, 12 months, 24 months, and 5 years after the study subject is enrolled). Young-onset type 2 diabetes will be compared to see the difference in clinical presentations and responses to antidiabetic drugs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06111833
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Taichung Veterans General Hospital trials
Trials by the same sponsor.
- NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
- NCT07453953 — A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis · EARLY_PHASE1 · not yet recruiting
- NCT07487636 — 4DryField PH and Head and Neck Operations. · NA · enrolling by invitation
- NCT07284017 — The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients. · NA · not yet recruiting
- NCT07363876 — The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06111833 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taichung Veterans General Hospital
- Last refreshed: 1 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06111833.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing